How Meshima Inhibits MMP-9 to Prevent Cancer Spread

Meshima & Cancer Metastasis

80% lung metastasis reduction

At 100 mg/kg, a PL acidic polysaccharide reduced lung metastasis frequency in mice by 80%, connecting in vitro MMP-9 inhibition data to a measurable animal outcome.

Han et al., International Immunopharmacology, 2006

2

independent pathways by which Meshima suppresses MMP-9

MMP-2/9

both gelatinases blocked by hispolon in hepatoma cells (Huang 2010)

4

cancer types with published PL MMP inhibition data

Han et al., International Immunopharmacology, 2006

View as image ↗

Cancer cells don't kill by staying in one place. They kill by spreading to distant organs. To do this, cancer cells must first dissolve the protein barriers surrounding the tissue they're leaving. The primary enzyme that makes this possible is MMP-9 (matrix metalloproteinase-9), a gelatinase that breaks down type IV collagen, the structural protein forming the walls between tissue compartments. Meshima MMP-9 inhibition has been documented in cell studies across four cancer types, with two separate classes of Meshima compounds (hispolon, a phenolic compound, and the mushroom's polysaccharide fraction) suppressing this enzyme through entirely different signaling routes.^[1][2] This is a cluster article within the Meshima mushroom guide; all evidence reviewed here is preclinical, with no human clinical trials measuring MMP-9 endpoints.

What MMP-9 Is and Why Cancer Cells Depend on It to Spread

Every cell in the body lives inside a protein scaffold. Basement membranes, thin sheets of type IV collagen and other structural proteins, separate tissue compartments from each other and from the bloodstream. This scaffolding is not just physical support: it is the primary barrier between a localized tumor and the rest of the body.

For a cancer cell to metastasize, it must cross this barrier at least twice. First, it must break through its home tissue's basement membrane to reach a blood vessel (a step called intravasation). Second, after traveling through the bloodstream, it must break through the vessel wall again to establish a new colony at a distant site (called extravasation). Without the ability to dissolve basement membrane collagen, cancer cells are trapped.

MMP-9 is one of two principal enzymes cancer cells use to dissolve this barrier. Formally, MMP-9 is a gelatinase: it specifically liquefies type IV collagen, the form of collagen that dominates basement membranes. When cancer cells secrete MMP-9 into surrounding tissue, the collagen matrix breaks down, gaps open, and cells can move through. Elevated MMP-9 activity is associated with aggressive, late-stage disease across most cancer types.

MMP-2 is the other main gelatinase and often works alongside MMP-9. Research has shown that suppressing MMP-9 alone, or both together, reduces cancer cell invasion in experimental models. This made both enzymes attractive drug targets from the 1990s onward.

Why 30 Years of MMP Inhibitor Drugs Mostly Failed, and What That Means for Meshima

From the mid-1990s through the early 2000s, more than 50 broad-spectrum MMP inhibitor drugs entered clinical trials. Most failed in Phase II or Phase III. The problem was not lack of mechanism; it was lack of selectivity.

MMPs are not only used by cancer. The body relies on a broad family of MMP enzymes for wound healing, normal tissue remodeling, and immune cell trafficking. Broad-spectrum inhibition blocked these normal functions, causing musculoskeletal pain and stiffness that dose-limited the drugs before they could achieve tumor effect. Worse, some MMPs actually suppress tumor growth; blocking them uniformly could remove protective activity.

The lesson the pharmaceutical field took from this: selective inhibition of specific MMPs, particularly MMP-9, through targeted upstream pathways is more likely to succeed than broad enzyme-level blockade.

This history is relevant for interpreting the meshima data. Hispolon does not appear to act as a direct, enzyme-blocking MMP-9 inhibitor. Instead, it suppresses the signaling pathways that drive MMP-9 production: FAK, PI3K/Akt, RhoA, and ERK1/2. This upstream, pathway-level suppression is mechanistically closer to what cancer pharmacologists now consider a more tractable approach than what the 1990s MMP inhibitor programs attempted.

That does not mean the clinical translation is guaranteed. But the mechanism is not the one that failed repeatedly in trials.

Hispolon's Direct Attack on MMP-9 via FAK and ERK Pathways

Hispolon is a phenolic compound isolated from Phellinus linteus. Its relationship to the broader Meshima bioactive compound profile is covered in the Phellinus linteus bioactive compounds article.

In 2010, Huang and colleagues published a cell study in SK-Hep1 hepatoma cells, a human liver cancer cell line, examining hispolon's effects on invasion markers.^[1]

The results were concentration-dependent: as hispolon dose increased, MMP-2 and MMP-9 expression in the cells fell. Urokinase-plasminogen activator (uPA), a separate protease that cancer cells also use to dissolve surrounding tissue, was also suppressed.

The mechanism Huang traced runs through two overlapping signaling pathways.

Pathway 1: FAK to PI3K/Akt to RhoA. Focal adhesion kinase (FAK) is a protein that cancer cells activate when they attach to the extracellular matrix; that attachment is the first step in invasion. FAK then stimulates PI3K/Akt, a survival and motility signaling complex. Akt activates RhoA, a molecular switch that regulates the cell's internal scaffolding and drives MMP-9 production. Hispolon suppressed all of these in sequence.

Pathway 2: ERK1/2. ERK1/2 (extracellular signal-regulated kinase) is a parallel invasion signaling pathway also known to drive MMP expression. Huang confirmed this independently: adding PD98256, a drug known to block ERK1/2, also reduced MMP-2 and MMP-9. This confirmed ERK1/2 as a second, parallel pathway hispolon suppresses.

The result is that hispolon appears to reduce MMP-9 production by simultaneously blocking two separate signaling inputs that drive it. Cancer cells trying to maintain MMP-9 output face suppression from both routes at once.

A Second Route to the Same Target: Polysaccharides and Wnt/β-catenin

Hispolon is not the only Meshima compound class that suppresses MMP-9. Song and colleagues, writing in BMC Cancer in 2011, found that protein-bound polysaccharide from PL inhibited MMP-9 through a completely different molecular pathway, Wnt/β-catenin signaling, in SW480 human colon cancer cells.^[2]

Wnt/β-catenin is one of the most studied cancer pathways. When it is active, β-catenin enters the cell nucleus and turns on genes for cell growth and invasion, including MMP-9 and cyclin D1 (a protein that drives cell division). Disrupting this pathway suppresses MMP-9 production at the transcription level: the cell stops making the instructions to build MMP-9 in the first place.

At concentrations from 125 to 1,000 micrograms per milliliter, PL polysaccharide significantly inhibited cell growth, decreased β-catenin and cyclin D1, and reduced both MMP-9 activity and cell motility in a dose-dependent pattern.

Song also extended the finding into an in vivo xenograft experiment: SW480 cells were transplanted into nude mice, and the mice receiving PL polysaccharide showed significantly reduced tumor growth, an increased percentage of dying cells in tumor tissue, and decreased β-catenin expression in those tumors. The in vitro MMP-9 suppression appeared to translate into slowed tumor growth in the animal model.

The key structural point: hispolon hits MMP-9 via FAK/PI3K/Akt/RhoA and ERK1/2. Polysaccharides hit MMP-9 via Wnt/β-catenin. These are independent inputs to the same output. A cancer cell trying to maintain MMP-9 activity while facing hispolon-driven ERK1/2 suppression cannot simply switch to the Wnt/β-catenin route, because the polysaccharide fraction suppresses that route simultaneously. The two-pathway redundancy is what makes the full-mushroom extract story more mechanistically interesting than either compound alone.

MMP Inhibition Across Cancer Types: Breast and Thyroid

The hepatoma and colon cancer findings are the most detailed mechanistic data, but PL's MMP-suppressing effects have been tested in other cancer types.

In 2022, Yu and colleagues tested PL polysaccharide in thyroid carcinoma cells.^[5] Beyond reducing MMP expression, they documented something the earlier studies did not: PL polysaccharide altered EMT (epithelial-mesenchymal transition) markers in the cancer cells.

EMT is a biological program that transforms cancer cells from an epithelial state (static, adherent, specialized) into a mesenchymal state: mobile, invasive, and capable of surviving in the bloodstream. The transformation is marked by three proteins. E-cadherin, the "stay-attached" protein, falls when EMT activates. N-cadherin and vimentin, proteins associated with motility and flexibility, rise. In cells undergoing EMT, this switch makes the cancer cell biologically inclined to move.

PL polysaccharide reversed this pattern: E-cadherin went up; N-cadherin and vimentin went down. The cells started returning to a less invasive phenotype. MMP reduction in these cells is consistent with that EMT reversal: less invasive cells produce less MMP-9.

For breast cancer, Sliva and colleagues found that PL extract suppressed adhesion, migration, and invasion of MDA-MB-231 cells, one of the most aggressive and well-studied invasive breast cancer lines, through urokinase-plasminogen activator (uPA) suppression and AKT inhibition.^[4] The uPA/AKT mechanism is parallel to, not identical with, the MMP-9 pathways. uPA is a different enzyme that cancer cells use to dissolve extracellular matrix; blocking it alongside MMP-9 removes two separate tools from the metastasis toolkit. Sliva also found that PL inhibited VEGF-mediated angiogenesis in the same cells, a finding explored in the Meshima angiogenesis article.

The spectrum now covers hepatoma, colon, thyroid, and breast cancer. Different cancer types, different cell lines, different research teams, converging on similar MMP or invasion-suppression findings.

From Cell Dish to Living Animals: The 80% Metastasis Number

Cell studies show MMP-9 suppression. Animal studies test whether that suppression actually prevents cancer from spreading through a living body.

In 2006, Han and colleagues tested acidic polysaccharide from PL in a mouse melanoma metastasis model.^[3] Mice were injected with B16F10 melanoma cells, a highly metastatic line commonly used in metastasis research, and then treated with PL polysaccharide at three dose levels. Lung metastasis frequency was the endpoint.

The dose-response was striking:

• At 10 mg/kg: 30% reduction in lung metastasis frequency
• At 30 mg/kg: 77% reduction
• At 100 mg/kg: 80% reduction

Han also confirmed that the mechanism was not direct cancer cell killing. PL polysaccharide showed no direct cytotoxicity on the cancer cells in this study. Instead, two mechanisms accounted for the metastasis reduction: direct inhibition of cancer cell adhesion to the extracellular matrix (preventing the first step of invasion) and immunopotentiation: increased macrophage nitric oxide production, which enhances the immune system's capacity to destroy circulating cancer cells.

The 80% lung metastasis reduction figure is the most striking quantitative finding in the Meshima metastasis research and is essentially absent from consumer health content on the mushroom. It should be read with appropriate context: B16F10 is a highly aggressive and somewhat artificial model, the doses tested (especially 100 mg/kg) are very high, and melanoma metastasis in mice does not map directly to human cancer biology. Still, the animal model provides meaningful evidence that in vitro MMP and adhesion suppression corresponds to a real-world outcome in a living system.

The full metastasis evidence picture is in the Meshima cancer metastasis overview. The related cancer cell migration research is covered in the Phellinus linteus migration inhibition article.

What the Research Cannot Tell Us Yet

The mechanistic detail reviewed here, two independent pathways suppressing MMP-9, four cancer types, and animal model data with 80% metastasis reduction, is among the most sophisticated in the functional mushroom literature. It is also entirely preclinical.

The questions that remain open are fundamental ones.

Bioavailability. Do hispolon and PL polysaccharides, when consumed orally by humans, reach cancer tissue at concentrations comparable to those used in the cell studies? Cell study concentrations are direct-exposure experiments. Human oral absorption involves digestion, liver processing, and distribution across the whole body, with no evidence yet that tumor-relevant concentrations are achieved.

Human MMP-9 endpoints. No clinical trial has measured MMP-9 levels in patients taking meshima extract, before or after treatment. The intermediate step between "suppresses MMP-9 in a hepatoma cell line" and "reduces metastasis in cancer patients" is entirely unstudied.

The MMPI history. The clinical failure of broad-spectrum MMP inhibitors in the 2000s means the field has good reason for caution. Hispolon's upstream, pathway-level approach to MMP-9 suppression is mechanistically preferable to enzyme-level blockade, but that distinction has not been tested in humans.

Comparison to other MMP-9 research. Several compounds from other plants (EGCG from green tea, curcumin from turmeric) have also shown MMP-9 inhibition in cell studies, and some have more translational data. Meshima has the advantage of showing two independent pathways, but the clinical translation gap for all natural MMP-9 inhibitors remains wide.

What the research does establish: Meshima contains compounds that suppress MMP-9 through multiple molecular pathways in multiple cancer models. That is a meaningful mechanistic finding. The distance between that finding and clinical proof remains significant.

The Bottom Line

Meshima contains two compound classes that inhibit MMP-9 through independent molecular pathways: hispolon via FAK/PI3K/Akt/RhoA and ERK1/2 suppression in hepatoma cells (Huang 2010), and polysaccharides via Wnt/β-catenin disruption in colon cancer cells (Song 2011). Additional data shows MMP suppression and EMT reversal in thyroid carcinoma (Yu 2022), uPA and AKT inhibition in breast cancer (Sliva 2008), and an 80% reduction in lung metastasis frequency in mice at 100 mg/kg (Han 2006). All data is preclinical; no human trials have measured meshima's effect on MMP-9 or metastasis outcomes, and clinical translation of MMP inhibition has a difficult history in pharmaceutical research.

Frequently Asked Questions

What is MMP-9 and why is it important in cancer?

MMP-9 (matrix metalloproteinase-9) is a gelatinase enzyme that cancer cells secrete to dissolve type IV collagen, the main protein forming the barriers between tissue compartments. Without MMP-9, cancer cells cannot break through the basement membrane to enter the bloodstream and establish new tumors at distant sites. Elevated MMP-9 is associated with aggressive, late-stage disease across most cancer types, making it a long-studied drug target.

How does MMP-9 promote cancer metastasis?

Cancer cells use MMP-9 at two critical steps in metastasis: dissolving the basement membrane to escape their original tissue and enter a blood vessel (intravasation), and dissolving the vessel wall to exit the bloodstream and colonize a new organ (extravasation). MMP-9 is a gelatinase: it specifically liquefies type IV collagen, the form of collagen that dominates these barriers. Without this enzyme, cancer cells are confined to their original location.

What natural compounds inhibit MMP-9?

Several plant and mushroom compounds have shown MMP-9 inhibition in cell studies, including EGCG from green tea, curcumin from turmeric, and hispolon and polysaccharides from Meshima (Phellinus linteus). Meshima is notable for inhibiting MMP-9 through two independent pathways simultaneously. All of these findings come from laboratory experiments; human clinical evidence for any natural MMP-9 inhibitor remains limited.

Does hispolon block MMP-9 in cancer cells?

Yes, in cell studies. Huang and colleagues showed that hispolon reduced MMP-9 and MMP-2 expression in SK-Hep1 human hepatoma cells in a concentration-dependent pattern, through FAK, PI3K/Akt, RhoA, and ERK1/2 pathway suppression (2010). These are in vitro findings. No human data exists showing that orally consumed hispolon reaches tumor tissue at concentrations comparable to those used in the laboratory experiments.

Why do researchers target MMP-9 to stop cancer from spreading?

MMP-9 is one of two gelatinase enzymes critical for cancer invasion and metastasis. Without it, cancer cells cannot easily cross tissue barriers to spread. Blocking MMP-9 specifically, rather than the broader MMP enzyme family, became a priority after broad-spectrum MMP inhibitor drugs failed in clinical trials in the 2000s due to side effects and suppression of protective MMP activity. Selective MMP-9 targeting through upstream signaling pathways is now seen as a more tractable approach.

Sources & References

1. 1RTHM-00344·Huang, Guan-Jhong et al. (2010). “Hispolon suppresses SK-Hep1 human hepatoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen activator through the PI3K/Akt and ERK signaling pathways..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
2. 2RTHM-00437·Song, Kyoung-Sub et al. (2011). “Protein-bound polysaccharide from Phellinus linteus inhibits tumor growth, invasion, and angiogenesis and alters Wnt/β-catenin in SW480 human colon cancer cells..” BMC cancer.Study breakdown →PubMed →↩
3. 3RTHM-00185·Han, Sang-Bae et al. (2006). “Acidic polysaccharide from Phellinus linteus inhibits melanoma cell metastasis by blocking cell adhesion and invasion..” International immunopharmacology.Study breakdown →PubMed →↩
4. 4RTHM-00271·Sliva, D et al. (2008). “Phellinus linteus Extract in Breast-Cancer Cell Models: What This 2008 Study Actually Found.” British journal of cancer.Study breakdown →PubMed →↩
5. 5RTHM-01643·Yu, Kun et al. (2022). “Systematic evaluation of the anti-tumor effect of Phellinus linteus polysaccharide in thyroid carcinoma in vitro..” Molecular biology reports.Study breakdown →PubMed →↩